Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib in Relapsed/Refractory Mantle Cell Lymphoma
NCT02042950Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2014
- Primary completion
- Dec 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 21 months. Started Jul 2014; status: terminated.
02
Drugs
carfilzomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02042950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042950.